scholarly journals Histopathological Spectrum of Central Nervous System Lesions in a Tertiary Care Hospital in Eastern India

2021 ◽  
Vol 8 (18) ◽  
pp. 1304-1310
Author(s):  
Sujata Naik ◽  
Nibedita Sahoo ◽  
Bishwaranjan Mohanty ◽  
Anasuya Lenka ◽  
Ajit Surya Mohapatra ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cell Lymphoma ◽  
Tertiary Care ◽  
B Cell Lymphoma ◽  
World Health ◽  
Eastern India ◽  
Large B Cell Lymphoma ◽  
Neoplastic Lesions ◽  
Cns Tumours

BACKGROUND Tumours of central nervous system (CNS) are reported to be less than 2 % of all malignancies. In India, CNS tumours constitute about 1.9 % of all tumours. The CNS space occupying lesions cause grave life-threatening outcomes irrespective of their nature as they grow in a confined space and are present close to vital structures. Hence, it is of great importance to establish the accurate diagnosis for proper and timely neurosurgical intervention. METHODS This was a retrospective study carried out in a tertiary care teaching hospital which caters as a referral unit for neurosurgical cases in Eastern India, for a duration of one and half year (January 2018 - July 2020) among 185 cases of CNS lesions collected from archives of Department of Pathology. The tumours were reclassified and graded according to the most recent World health organisation (WHO) classification of CNS tumours (2016). RESULTS Neoplastic lesions (168 cases, 91.35 %) were commoner than non-neoplastic entities and amongst the neoplastic lesions, meningioma was the commonest entity followed by diffuse astrocytic and oligodendroglial tumours while least incidence was noted for neuronal and mixed neuronal glial tumours. Out of all the tumours for which World Health Organization (WHO) grading was done, highest was WHO grade I (80 cases, 54.8 %) and least was grade III tumours (10 cases, 6.8 %). Male predominance was seen overall except in meningioma. Some rare and interesting cases like solitary fibrous tumour / hemangiopericytoma (anaplastic type), primary CNS diffuse large B cell lymphoma (DLBCL), CNS plasmacytoma which we came across are also highlighted. CONCLUSIONS The present study helps to provide information regarding the disease burden in our area. This study attempts to categorise various CNS neoplasms as per recent WHO classification (2016) which has not only diagnostic implication but also has significant prognosis and predictive value. KEYWORDS Central Nervous System, Immunohistochemistry, Eastern India, Meningioma, Solitary Fibrous Tumour / Hemangiopericytoma, Diffuse Large B Cell Lymphoma

Evolving Treatments for Primary Central Nervous System Lymphoma

2019 ◽  
pp. 454-466 ◽  
Author(s):  
Andrés J.M. Ferreri ◽  
Matthias Holdhoff ◽  
Lakshmi Nayak ◽  
James L. Rubenstein
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
Disease Free Survival ◽  
B Cell Lymphoma ◽  
World Health ◽  
High Dose ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Primary central nervous system (CNS) lymphoma (PCNSL) is an aggressive form of non-Hodgkin lymphoma that remains confined to the CNS neuroaxis during its natural history of disease and is therefore considered stage IE disease. PCNSL is diffuse large B-cell lymphoma (DLBCL) morphology in more than 95% of patients and is designated primary diffuse large B-cell lymphoma of the CNS on the basis of the 2017 World Health Organization classification of hematopoietic and lymphoid tumors. Rapidly evolving therapeutic paradigms have been linked to evidence of progress in PCNSL, a disease long considered to be incurable. Increasing evidence supports the need for efficient diagnosis, staging, and initiation of therapy, ideally at centers with experience with this type of brain cancer. High-dose methotrexate (MTX) remains a cornerstone of induction regimens, and most data support the use of rituximab. However, clinical research challenges must address key questions, including the development of ever more effective and less toxic induction regimens and the selection of the most appropriate and effective consolidation approaches, as well as the fact that, increasingly, PCNSL affects older patients who do not tolerate strong genotoxic irradiation or high-dose chemotherapy (HDC)-based strategies. Maintenance therapy, immunotherapy, and the implementation of targeted agents on the basis of the molecular and biologic properties of the disease create opportunities for precision medicine and the potential for long-term disease-free survival and cure, with minimal treatment-related neurotoxicity, for a greater fraction of patients.

scholarly journals T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma

Rare Tumors ◽  
2015 ◽  
Vol 7 (4) ◽  
pp. 160-162 ◽  
Author(s):  
Pooja Advani ◽  
Jason Starr ◽  
Abhisek Swaika ◽  
Liuyan Jiang ◽  
Yushi Qiu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Central nervous system relapse in diffuse large B-cell lymphoma: analysis of risk factors and a new prognostic model

2015 ◽  
Vol 26 ◽  
pp. vii85
Author(s):  
Yusuke Kanemasa ◽  
Tatsu Shimoyama ◽  
Yuki Sasaki ◽  
Sawada Takeshi ◽  
Eisaku Sasaki ◽  
...  
Keyword(s):  
Risk Factors ◽  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Prognostic Model ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Central Nervous System Relapse ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Primary Central Nervous System Lymphoma: Diffuse Large B-Cell Lymphoma

2019 ◽  
Vol 25 (4) ◽  
pp. 239-242
Author(s):  
Asuman Ali ◽  
Cemile Haki ◽  
Fatma Öz Atalay ◽  
Ramazan Yalçın
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Cell Lymphoma ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document